Zaipul I. Md Dom

Zaipul I. Md Dom

Auto-generated profile, based on publicly available information

Zaipul I. Md Dom

Research Division, Joslin Diabetes Center, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
DHDaigoro Hirohama
Daigoro Hirohama
AAAmin Abedini
Amin Abedini
SMSalina Moon
Salina Moon
ASAditya Surapaneni
Aditya Surapaneni
SDSimon Dillon
Simon Dillon
KSKatalin Susztak
Katalin Susztak
Significance Statement: Although gene expression changes have been characterized in human diabetic kidney disease (DKD), unbiased tissue proteomics information for this condition is lacking. The authors conducted an unbiased aptamer-based proteomic analysis of samples from patients with DKD and healthy controls, identifying proteins with levels that associate with kidney function (eGFR) or fibrosis, after adjusting for key covariates. Overall, tissue gene expression only modestly correlated with tissue protein levels. Kidney protein and RNA levels of matrix metalloproteinase 7 (MMP7) strongly correlated with fibrosis and with eGFR. Single-cell RNA sequencing indicated that kidney tubule cells are an important source of MMP7. Furthermore, plasma MMP7 levels predicted future kidney function decline. These findings identify kidney tissue MMP7 as a biomarker of fibrosis and blood MMP7 as a biomarker for future kidney function decline. Background: Diabetic kidney disease (DKD) is responsible for close to half of all ESKD cases. Although unbiased gene expression changes have been extensively characterized in human kidney tissue samples, unbiased protein-level information is not available. Methods: We collected human kidney samples from 23 individuals with DKD and ten healthy controls, gathered associated clinical and demographics information, and implemented histologic analysis. We performed unbiased proteomics using the SomaScan platform and quantified the level of 1305 proteins and analyzed gene expression levels by bulk RNA and single-cell RNA sequencing (scRNA-seq). We validated protein levels in a separate cohort of kidney tissue samples as well as in 11,030 blood samples. Results: Globally, human kidney transcript and protein levels showed only modest correlation. Our analysis identified 14 proteins with kidney tissue levels that correlated with eGFR and found that the levels of 152 proteins correlated with interstitial fibrosis. Of the identified proteins, matrix metalloprotease 7 (MMP7) showed the strongest association with both fibrosis and eGFR. The correlation between tissue MMP7 protein expression and kidney function was validated in external datasets. The levels of MMP7 RNA correlated with fibrosis in the primary and validation datasets. Findings from scRNA-seq pointed to proximal tubules, connecting tubules, and principal cells as likely cellular sources of increased tissue MMP7 expression. Furthermore, plasma MMP7 levels correlated not only with kidney function but also associated with prospective kidney function decline. Conclusions: Our findings, which underscore the value of human kidney tissue proteomics analysis, identify kidney tissue MMP7 as a diagnostic marker of kidney fibrosis and blood MMP7 as a biomarker for future kidney function decline.

10 August 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
HKHiroki Kobayashi
Hiroki Kobayashi
HLHelen C. Looker
Helen C. Looker
ESEiichiro Satake
Eiichiro Satake
FDFrancesca D'Addio
Francesca D'Addio
JWJonathan M. Wilson
Jonathan M. Wilson
AKAndrzej S. Krolewski
Andrzej S. Krolewski
Circulating proteins associated with transforming growth factor–β (TGF-β) signaling are implicated in the development of diabetic kidney disease (DKD). It remains to be comprehensively examined which of these proteins are involved in the pathogenesis of DKD and its progression to end-stage kidney disease (ESKD) in humans. Using the SOMAscan proteomic platform, we measured concentrations of 25 TGF-β signaling family proteins in four different cohorts composed in total of 754 Caucasian or Pima Indian individuals with type 1 or type 2 diabetes. Of these 25 circulating proteins, we identified neuroblastoma suppressor of tumorigenicity 1 (NBL1, aliases DAN and DAND1), a small secreted protein known to inhibit members of the bone morphogenic protein family, to be most strongly and independently associated with progression to ESKD during 10-year follow-up in all cohorts. The extent of damage to podocytes and other glomerular structures measured morphometrically in 105 research kidney biopsies correlated strongly with circulating NBL1 concentrations. Also, in vitro exposure to NBL1 induced apoptosis in podocytes. In conclusion, circulating NBL1 may be involved in the disease process underlying progression to ESKD, and its concentration in circulation may identify subjects with diabetes at increased risk of progression to ESKD.

30 June 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ZDZaipul I. Md Dom
Zaipul I. Md Dom
ESEiichiro Satake
Eiichiro Satake
JSJan Skupien
Jan Skupien
BKBozena Krolewski
Bozena Krolewski
KOKristina O’nEil
Kristina O’nEil
AKAndrzej S. Krolewski
Andrzej S. Krolewski
Global proteomics profiling identified FGF20, TNFSF12, and ANGPT1 as protective against progression of renal function decline in those with diabetes.

7 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZDZaipul I. Md Dom
Zaipul I. Md Dom
SMSalina Moon
Salina Moon
ESEiichiro Satake
Eiichiro Satake
DHDaigoro Hirohama
Daigoro Hirohama
NANicholette Allred
Nicholette Allred
MNMonika A. Niewczas
Monika A. Niewczas
Diabetic kidney disease (DKD) progression is not well understood. Using high-throughput proteomics, biostatistical, pathway and machine learning tools, we examine the urinary Complement proteome in two prospective cohorts with type 1 or 2 diabetes and advanced DKD followed for 1,804 person-years. The top 5% urinary proteins representing multiple components of the Complement system (C2, C5a, CL-K1, C6, CFH and C7) are robustly associated with 10-year kidney failure risk, independent of clinical covariates. We confirm the top proteins in three early-to-moderate DKD cohorts (2,982 person-years). Associations are especially pronounced in advanced kidney disease stages, similar between the two diabetes types and far stronger for urinary than circulating proteins. We also observe increased Complement protein and single cell/spatial RNA expressions in diabetic kidney tissue. Here, our study shows Complement engagement in DKD progression and lays the groundwork for developing biomarker-guided treatments.

22 May 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
ZCZhuo Chen
Zhuo Chen
ESEiichiro Satake
Eiichiro Satake
MPMarcus G. Pezzolesi
Marcus G. Pezzolesi
ZDZaipul I. Md Dom
Zaipul I. Md Dom
DSDevorah Stucki
Devorah Stucki
RNRama Natarajan
Rama Natarajan
Variation in DNA methylation (DNAmet) in white blood cells and other cells/tissues has been implicated in the etiology of progressive diabetic kidney disease (DKD). However, the specific mechanisms linking DNAmet variation in blood cells with risk of kidney failure (KF) and utility of measuring blood cell DNAmet in personalized medicine are not clear. We measured blood cell DNAmet in 277 individuals with type 1 diabetes and DKD using Illumina EPIC arrays; 51% of the cohort developed KF during 7 to 20 years of follow-up. Our epigenome-wide analysis identified DNAmet at 17 CpGs (5′-cytosine-phosphate-guanine-3′ loci) associated with risk of KF independent of major clinical risk factors. DNAmet at these KF-associated CpGs remained stable over a median period of 4.7 years. Furthermore, DNAmet variations at seven KF-associated CpGs were strongly associated with multiple genetic variants at seven genomic regions, suggesting a strong genetic influence on DNAmet. The effects of DNAmet variations at the KF-associated CpGs on risk of KF were partially mediated by multiple KF-associated circulating proteins and KF-associated circulating miRNAs. A prediction model for risk of KF was developed by adding blood cell DNAmet at eight selected KF-associated CpGs to the clinical model. This updated model significantly improved prediction performance (c-statistic = 0.93) versus the clinical model (c-statistic = 0.85) at P = 6.62 × 10 −14 . In conclusion, our multiomics study provides insights into mechanisms through which variation of DNAmet may affect KF development and shows that blood cell DNAmet at certain CpGs can improve risk prediction for KF in T1D.

10 October 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
AKAndrzej S. Krolewski
Andrzej S. Krolewski
JHJani K. Haukka
Jani K. Haukka
ZDZaipul I. Md Dom
Zaipul I. Md Dom
VCViktor R. Curovic
Viktor R. Curovic
CWChunyi Wu
Chunyi Wu
ADAlessandro Doria
Alessandro Doria
Key Points: A custom-made Joslin OLINK proteomics platform was developed to quantify 21 Joslin kidney panel (JKP) proteins in circulation to predict ESKD risk. Each JKP protein discriminated moderately/well ESKD risk in diabetes; optimal predictive model included three clinical markers and eight JKP proteins. In the type 2 diabetes subgroup from the Action to Control Cardiovascular Risk in Diabetes trial, three JKP proteins identified subjects in whom fenofibrate dramatically reduced risk of fast kidney decline. Background: To facilitate personalized treatment of diabetic kidney disease (DKD), we developed the Joslin kidney panel (JKP) of 21 circulating proteins associated with progression to ESKD. Prognostic models using baseline concentrations of JKP proteins in circulation and clinical markers were then developed to stratify individuals according to ESKD risk and according to response to fenofibrate, a potential renoprotective drug. Methods: The custom-made Joslin OLINK multipurpose proteomics platform was used to quantify JKP proteins. Association between baseline serum/plasma concentrations of these proteins and kidney outcomes was examined in five independent study groups. Results: In type 1 diabetes individuals from Joslin ( N =59), FinnDiane ( N =389), and Steno ( N =283), all JKP proteins were good discriminators of ESKD risk during a 10-year follow-up. Baseline concentrations of KIM-1 and WFDC2 performed the best, matching or outperforming the clinical markers. An optimal model to discriminate ESKD risk that included three clinical markers and eight JKP proteins (KIM1, TNF-R2, TNF-R3, TNF-R19L, PVRL4, WFDC2, DLL1, and SYND1) was developed using the FinnDiane cohort (C-index 0.868, SEM±0.019) and validated in the Steno cohort (C-index 0.913, SEM±0.104) and in type 2 diabetes Joslin study (C-index 0.807, SEM±0.036). In each of these studies, the optimal model performed better than models based solely on three clinical markers. In a subgroup of 450 individuals with type 2 diabetes from the Action to Control Cardiovascular Risk in Diabetes-Lipid trial, high levels of three JKP proteins (EFNA4, DLL1, IL-1RT1) predicted amelioration of fast kidney function decline during 4 years of follow-up in those treated with fenofibrate compared with placebo. Conclusions: Quantification of circulating JKP proteins using the Joslin OLINK platform discriminates ESKD risk in individuals with diabetes and their response to renoprotective drugs. The use of this multipurpose precision medicine tool should facilitate studies on the etiology of DKD and enable the development of effective personalized treatment protocols for individuals with DKD.